General information
Guardant Health, Inc
505 Penobscot Dr.
94063 Redwood City, California
USA
Contact person: Helmy Eltoukhy, Chief Executive Officer and Chairman
Company main phone: +1 (855) 6988887
Company main fax: +1 (888) 9744258
Website: https://www.guardanthealth.com
Year founded: | 2012
|
Source of foundation: | Independent foundation |
No. of employees: |
Worldwide: 1793 |
Corporate description / mission:
Guardant Health is a precision oncology company focused on cancer diagnostics through use of the proprietary blood tests, vast data sets and advanced analytics. Guardant Health has commercially launched Guardant360®, Guardant360® CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced-stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the Shield™ test, aims to address the needs of individuals eligible for cancer screening.
State of ownership: Publicly listed on stock exchange
Headquarters: Yes
IPO (year): 2018
Categorization
Sector: |
- Biotechnology - Therapeutics and Diagnostics
|
Subsector: |
- Molecular diagnostics
- Other
|
Primary therapeutic areas: |
- Neoplasms / cancer / oncology
|
Business model: |
- Manufacturer
- R&D
- Service company
- Supplier / Distributor
|
Customer segments: |
- Consumers (mass market)
- Hospitals
- Large medtech
- Physicians / doctors
|
Summary Products / Services / Technologies
Description of products:
Guardant360® CDx
Guardant Reveal™ test
LUNAR-2 test
Financing details
Fiscal year (end of) 2022
Revenues: | USD 449.54M | |
R&D expenses: | USD 373.81M | |
No. of shares: | 102'664'000 | |
Market cap. / valuation: | USD 2'664.13M | |
Collaborations & Clients
Partnering strategy / collaborations:
The company work with bio-pharmaceutical partners, digital health companies, patient advocacy groups and international distributors.